Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00407745 · ClinicalTrials.gov registry record · Phase 3

A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury

A Phase 3 study of Spinal Cord Injuries and Neuralgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

Completed
Registry status
Phase 3
Development phase
220
Enrollment target
20
Study locations

NCT00407745: Completed Phase 3 study of Spinal Cord Injuries and Neuralgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

NCT00407745 is a Phase 3 study of Spinal Cord Injuries and Neuralgia that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 220 participants, above the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (261% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00407745, a Phase 3 study of Spinal Cord Injuries and Neuralgia, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

COMPLETED
Registry status
Phase 3
Development phase
220 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate if pregabalin relieves nerve pain associated with spinal cord injury compared to placebo (pill that contains no active medicine). This study will also evaluate the safety of pregabalin in this patient population.

Primary Outcome

DAAC was derived from participant's daily pain diary, where pain was measured on an 11-point Numerical Rating Scale (NRS-Pain)ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). The DAAC was calculated as the mean of all daily pain diary rating post baseline minus the baseline score then multiplied by the proportion of the planned study duration completed by the participant.

Interventions

  • DRUG placebo
  • DRUG pregabalin

Study Locations (20)

California

  • Pfizer Investigational Site - Fresno
  • Pfizer Investigational Site - Napa
  • Pfizer Investigational Site - Northridge
  • Pfizer Investigational Site - Pasadena

Arizona

  • Pfizer Investigational Site - Phoenix
  • Pfizer Investigational Site - Phoenix
  • Pfizer Investigational Site - Phoenix

Florida

  • Pfizer Investigational Site - Miami
  • Pfizer Investigational Site - Miami
  • Pfizer Investigational Site - Orlando

New York

  • Pfizer Investigational Site - New York
  • Pfizer Investigational Site - White Plains

Pennsylvania

  • Pfizer Investigational Site - Johnstown
  • Pfizer Investigational Site - Philadelphia

Indiana

  • Pfizer Investigational Site - Indianapolis

Kansas

  • Pfizer Investigational Site - Overland Park

Michigan

  • Pfizer Investigational Site - Detroit

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2007-01
Est. Completion 2011-02
Phase Phase 3

What the finished NCT00407745 record still lists

NCT00407745 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (261% higher).

The record links to 2 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00407745 names 20 study sites across 11 states, led by California, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT00407745 about?

NCT00407745 is a clinical study titled "A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury". The purpose of this study is to evaluate if pregabalin relieves nerve pain associated with spinal cord injury compared to placebo (pill that contains no active medicine). This study will also evaluate the safety of pregabalin in this patient population.

What is the current status of trial NCT00407745?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2007-01. Estimated completion is 2011-02.

What conditions does trial NCT00407745 study?

This clinical trial studies the following conditions: Spinal Cord Injuries, Neuralgia.

What interventions are being tested in trial NCT00407745?

The interventions under investigation include: placebo (DRUG), pregabalin (DRUG).

Who is sponsoring clinical trial NCT00407745?

This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00407745 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Cord Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00407745's enrollment target sits among peer trials

220 10th of 202 higher than 193 of 202 other Spinal Cord Injuries trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Spinal Cord Injuries trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00920972 · 220 participants · Phase 1

    Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

  • NCT01851642 · 220 participants

    Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

  • NCT02582021 · 220 participants

    WISE CVD - Continuation (WISE HFpEF)

  • NCT04067830 · 220 participants · Phase 2

    Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00407745, the US trial registry maintained by the National Library of Medicine. NCT00407745 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.